There is some real momentum behind the market now, so I think we should see stocks build on their gains.
I think it's still a very important piece of legislation. The importance is the preservation of the eligibility for funding for embryonic stem cell research.
It's a huge victory for people suffering from diseases or injuries.
The market really wants to carry on going up and there is a lot of optimism about this results season. We're not as confident as a lot of others because we think the economic fundamentals are still showing signs of weakness.
You're getting rid of the disease in the bone marrow. I think that the efficacy is unquestionable.
We welcome the surprise announcement from the governor, coupled with House Bill 1, which has language that will ensure scientific integrity and ensure this money is given out on a scientific, peer-review basis. It's huge for the community.